Reporting from ASCO 2022 Annual Meeting in Chicago, Nadia Harbeck discusses the practice changing results from DESTINY-Breast04 testing trastuzumab deruxtecan vs physician's choice of treatment in HER2-low metastatic Breast Cancer, including safety profile data. She also comments the interesting results from the TROPiCS-02 trial testing sacituzumab govitecan vs physician's choice of treatment in HR-positive/HER2-negative pre-treated advanced Breast Cancer.
This video was supported with an unrestricted grant from Bayer Healthcare.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.